Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix, Inc. (NASDAQ: CMRX) is a pioneering biopharmaceutical company focused on the development of innovative antiviral therapeutics. Led by a team of experienced professionals, Chimerix aims to enhance the quality of life for patients across diverse medical fields, including transplant, oncology, acute care, and global health.
Chimerix leverages its proprietary lipid technology, resulting in two promising clinical-stage compounds: CMX001 and CMX157. These compounds have shown potential for improved activity, bioavailability, and safety over existing drugs. The lead compound, CMX001, is a broad-spectrum antiviral that combats double-stranded DNA (dsDNA) viruses, such as cytomegalovirus (CMV), adenovirus, BK virus, herpes simplex virus, and variola (smallpox). CMX001 has completed Phase 2 development for CMV prophylaxis and is currently in Phase 2 trials for adenovirus treatment in hematopoietic stem cell transplant (HSCT) recipients.
Chimerix’s portfolio also includes ONC201, an oral, first-in-class small molecule imipridone targeting H3 K27M-mutant gliomas. The Phase 3 ACTION trial for ONC201 is a major focus, enrolling patients at over 130 sites in 13 countries. This study aims to report interim overall survival data by early 2025. Additionally, Chimerix's second-generation compound, ONC206, is undergoing Phase I dose escalation trials, demonstrating anti-cancer activity in both CNS and non-CNS tumors.
Financially, Chimerix maintains a robust balance sheet with significant capital to fund ongoing operations, reflecting sound fiscal management. The company reported a net loss of $18.6 million for Q2 2023 but continues to advance its research and development initiatives.
Chimerix’s mission is to develop medications that significantly improve and extend the lives of patients battling severe diseases. With ongoing clinical trials, strategic financial planning, and a dedicated team, Chimerix is poised to make substantial contributions to global health.
Chimerix (CMRX) will host a live conference call on November 4, 2021, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021, alongside an operational update. The call can be accessed via phone or through a live audio webcast available on the company's website. Notably, in June 2021, Chimerix received FDA approval for TEMBEXA, a treatment for smallpox. The company is also advancing ONC201, aimed at recurrent H3 K27M-mutant glioma, with efficacy results expected soon, and DSTAT, targeting acute myeloid leukemia.
Chimerix, a biopharmaceutical company, announced that CEO Mike Sherman and CFO Mike Andriole will participate in a pre-recorded fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference. The chat will be available on September 13, 2021, at 7:00 a.m. ET. Interested parties can access the audio webcast on Chimerix's Investor Relations website, where it will be archived for 90 days.
Chimerix is focused on developing innovative treatments for cancer and other serious diseases, with recent FDA approval for TEMBEXA for smallpox therapy.
Chimerix (NASDAQ:CMRX) announced FDA approval for TEMBEXA® (brincidofovir) as a smallpox treatment, marking its first FDA-approved drug. The approval extends to all age groups, including neonates, with a focus on oral formulations for easier administration. In Q2 2021, the company reported a net loss of $17.8 million and revenues of $0.4 million, down from $1.4 million in 2020. R&D expenses also rose to $13.8 million. Looking ahead, Chimerix plans to finalize TEMBEXA manufacturing and conduct important efficacy analyses for other therapies by the end of 2021.
DURHAM, N.C., Aug. 3, 2021 – Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will join a panel at the 2021 Wedbush PacGrow Healthcare Conference on August 10, 2021, at 10:55 a.m. ET. An audio webcast of the discussion will be available on Chimerix's Investor Relations website for 90 days.
The biopharmaceutical company focuses on cancer treatments and has recently gained FDA approval for TEMBEXA, a smallpox countermeasure. Chimerix is also advancing programs for ONC201 and DSTAT in serious diseases like acute myeloid leukemia.
Chimerix (NASDAQ:CMRX) has scheduled a conference call for August 5, 2021, at 8:30 a.m. ET to discuss its Q2 2021 financial results and operational updates. The company recently received FDA approval for TEMBEXA® to treat smallpox and is advancing its clinical programs, including ONC201 for recurrent H3 K27M-mutant glioma and dociparstat sodium (DSTAT) for acute myeloid leukemia. The press release highlights the ongoing clinical trials and the importance of upcoming reviews for ONC201.
Chimerix announced that the FDA has approved TEMBEXA (brincidofovir) for treating smallpox in patients of all age groups, including infants. This marks a significant milestone as it is the first smallpox antiviral approved since the disease's eradication. The approval is based on animal model studies demonstrating a survival benefit. Chimerix aims to collaborate with BARDA for a procurement contract to enhance pandemic preparedness. However, TEMBEXA carries a BOXED WARNING regarding increased mortality risk with prolonged use.
Chimerix (NASDAQ:CMRX) will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:00 a.m. ET. Mike Sherman, the CEO, will lead the presentation. A live audio webcast will be accessible in the Investor Relations section of Chimerix's website, where it will remain archived for about 90 days. Chimerix is focused on developing treatments for cancer and serious diseases, with key programs including brincidofovir, ONC201, and dociparstat sodium, targeting conditions such as smallpox and acute myeloid leukemia.
Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced its participation in the American Society of Clinical Oncology 2021 Annual Meeting, set for June 4-8, 2021. The company will present two oral presentations and one poster presentation, all on June 4. The oral presentations include topics on tracking tumor DNA in glioma patients and a Phase 2 study of ONC201 in neuroendocrine tumors. The poster will address a first-in-human dose escalation study of ONC206 in recurrent CNS neoplasms. Chimerix aims to develop impactful therapies for cancer and serious diseases.
Chimerix (NASDAQ:CMRX) announced participation in the Cowen and Company 2nd Annual Virtual Oncology Innovation Summit. CEO Mike Sherman and CFO Mike Andriole will engage in a fireside chat on May 20, 2021, at 10:00 a.m. ET. A live audio webcast will be accessible on Chimerix's Investor Relations section, archived for 90 days.
Chimerix focuses on developing innovative treatments for cancer and other serious diseases, with key programs including brincidofovir, ONC201, and dociparstat sodium.
Chimerix (NASDAQ:CMRX) reported its Q1 2021 financial results, revealing a net loss of $97.4 million, significantly higher than the $10.4 million loss from Q1 2020. Revenues increased slightly to $1.4 million from $1.2 million year-over-year. R&D expenses rose to $11.9 million, and total operational losses reached $97.5 million. Upcoming milestones include the PDUFA date for BCV for smallpox set for July 7, and progress in trials for DSTAT and ONC201. The company has $152.5 million in capital available for operations, but significant financial challenges remain.
FAQ
What is the current stock price of Chimerix (CMRX)?
What is the market cap of Chimerix (CMRX)?
What does Chimerix, Inc. do?
What are Chimerix's leading compounds?
What stages are Chimerix's clinical trials in?
How is Chimerix financially positioned?
What is the significance of the ONC201 Phase 3 ACTION trial?
What kind of partnerships does Chimerix have?
Where is Chimerix based?
How does Chimerix generate revenue?
What is unique about Chimerix’s lipid technology?
What is Chimerix's mission?
